Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals

References

• OngKLCheungBMManYBLauCPLamKSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension2007491697517159087
   PubMed Web of Science ®Google Scholar
• HajjarIKotchenTATrends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000JAMA2003290219920612851274
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDAdamsRCarnethonMHeart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20091193e21e18119075105
   PubMed Web of Science ®Google Scholar
• RosendorffCBlackHRCannonCPTreatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and PreventionCirculation2007115212761278817502569
   PubMed Web of Science ®Google Scholar
• PimentaEOparilSFixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combinationVasc Health Risk Manag20084365366418827915
   PubMedGoogle Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• LawesCMVander HoornSRodgersAGlobal burden of blood-pressure-related disease, 2001Lancet200837196231513151818456100
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens20091015 [E-pub ahead of print].
   Web of Science ®Google Scholar
• AppelLJGilesTDBlackHRASH position paper: dietary approaches to lower blood pressureJ Clin Hypertens (Greenwich)200911735836819583632
   PubMed Web of Science ®Google Scholar
• MoserMRationale for combination therapy in the management of hypertensionJ Clin Hypertens (Greenwich)200356Suppl 4172514688490
   PubMedGoogle Scholar
• CalhounDALacourciereYChiangYTGlazerRDTriple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trialHypertension2009541323919470877
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals CorporationNovartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure2009917 Available from: http://www.pharma.us.novartis.com/newsroom/press-release.jsp?PRID=2261 Accessed Apr 24, 2010.
   Google Scholar
• OparilSWeberMAngiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapyPostgrad Med20091212253919332960
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ20033267404142712829555
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• CostanzoPPerrone-FilardiPPetrettaMCalcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patientsJ Hypertens20092761136115119451836
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo, IncAZOR (amlodipine and olmesartan medoxomil tablets) Prescribing Information2009 Available from: http://www.azor.com/hcp/utilities/prescribing_information.html. Accessed Apr 24, 2010.
   Google Scholar
• PrisantLMCalcium antagonistsOparilSWeberMHypertension: A Companion to Brenner and Rector’s the Kidney2nd edPhiladelphiaElsevier2005683704
   Google Scholar
• MeredithPAElliottHLClinical pharmacokinetics of amlodipineClin Pharmacokinet199222122311532771
   PubMed Web of Science ®Google Scholar
• SchwochoLRMasonsonHNPharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjectsJ Clin Pharmacol200141551552711361048
   PubMed Web of Science ®Google Scholar
• RohatagiSLeeJShenoudaMPharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combinationJ Clin Pharmacol200848111309132218974285
   PubMed Web of Science ®Google Scholar
• BolbrinkerJHuberMScholzeJKreutzRPharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjectsFundam Clin Pharmacol200923676777419659504
   PubMed Web of Science ®Google Scholar
• GoodfriendTLAngiotensins: actions and receptorsIzzoJLJrBlackHRGoodfriendTLHypertension Primer: The Essentials of High Blood Pressure3rd edPhiladelphiaLippincott, Williams & Wilkins2003811
   Google Scholar
• MireDESilfaniTNPugsleyMKA review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blockerJ Cardiovasc Pharmacol200546558559316220064
   PubMed Web of Science ®Google Scholar
• WeberMAAngiotensin II receptor blockersIzzoJLJrBlackHRHypertension Primer, The Essentials of High Blood PressurePhiladelphiaLippincott, Williams & Wilkins2003430432
   Google Scholar
• KakutaHSudohKSasamataMYamagishiSTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Res2005251414615864875
   PubMedGoogle Scholar
• CareyRMWangZQSiragyHMRole of the angiotensin type 2 receptor in the regulation of blood pressure and renal functionHypertension2000351 Pt 215516310642292
   PubMed Web of Science ®Google Scholar
• KrumHCritical assessment of calcium antagonistsAust Fam Physician19972678418459232924
   PubMedGoogle Scholar
• ChrysantSMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909
   PubMed Web of Science ®Google Scholar
• OparilSLeeJKarkiSMelinoMSubgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication useJ Cardiovasc Pharmacol20095442743619730391
   PubMed Web of Science ®Google Scholar
• ChrysantSGLeeJMelinoMKarkiSHeyrmanREfficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertensionJ Hum Hypertens2010218 [E-pub ahead of print].
   Web of Science ®Google Scholar
• VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig20092911125
   PubMed Web of Science ®Google Scholar
• BarriosVBrommerPHaagUCalderonAEscobarCOlmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre StudyClin Drug Investig2009297427439
   PubMed Web of Science ®Google Scholar
• ChrysantSGOparilSMelinoMKarkiSLeeJHeyrmanREfficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertensionJ Clin Hypertens (Greenwich)200911947548219751459
   PubMed Web of Science ®Google Scholar
• VolpeMMieleCHaagUEfficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term studyClin Drug Investig2009296381391
   PubMed Web of Science ®Google Scholar
• MouradJJLe JeuneSEffective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009296419425
   PubMed Web of Science ®Google Scholar
• GossePLasserreRMinifieCLemetayerPClementyJBlood pressure surge on risingJ Hypertens20042261113111815167445
   PubMed Web of Science ®Google Scholar
• ChavanuKMerkelJQuanAMRole of ambulatory blood pressure monitoring in the management of hypertensionAm J Health Syst Pharm200865320921818216005
   PubMed Web of Science ®Google Scholar
• PickeringTGWhiteWBASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoringJ Clin Hypertens (Greenwich)2008101185085519128274
   PubMed Web of Science ®Google Scholar
• NeutelJMKereiakesDJPunziHEfficacy and safety of an amlodipine/olmesartan medoxomil-based titration regimen on blood pressure (BP) assessed by mean 24-hr ambulatory BP monitoring in patients with hypertensionJ Clin Hypertens200911Suppl 4A129
   Google Scholar
• HeagertyAMLaeisPHaagUOlmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy – additional effect by uptitration in patients with moderate-to-severe hypertensionJ Hypertens200927Suppl 4S283
   Google Scholar
• Daiichi Sankyo, Inc, ClinicalTrials.govBlood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension2009114 Available from: http://clinicaltrials.gov/ct2/show/NCT00527514 Accessed Apr 24, 2010.
   Google Scholar
• PunziHLewinAShojaeeAWaverczakWFDubielRXuJEfficacy of an amlodipine/olmesartan medoxomil-based titration regimen on blood pressure goal achievement in patients with hypertensionJ Clin Hypertens200911Suppl 4A133
   Google Scholar
• NeutelJMLittlejohnTIIIShojaeeAWaverczakWFDubielRXuJ24 hour efficacy of an amlodipine/olmesartan medoxomil-based titration regimen on blood pressure at daytime, nighttime and last 6, 4, 2 hours of dosing intervalJ Clin Hypertens200911Suppl 4A130
   Google Scholar
• SicaDAFixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?Drugs199448116247525192
   PubMed Web of Science ®Google Scholar
• LeenenFHWilsonTWBolliPPatterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoringCan J Cardiol199713109149209374947
   PubMed Web of Science ®Google Scholar
• PaesAHBakkerASoe-AgnieCJImpact of dosage frequency on patient complianceDiabetes Care19972010151215179314626
   PubMed Web of Science ®Google Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapyCongest Heart Fail20039632433214688505
   PubMedGoogle Scholar
• DicksonMPlauschinatCACompliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapyAm J Cardiovasc Drugs200881455018303937
   PubMed Web of Science ®Google Scholar
• SalehSSSzebenyiSCarterJAZacherCBellettiDPatterns and associated health services costs of antihypertensive drug modificationsJ Clin Hypertens (Greenwich)2008101435018174770
   PubMed Web of Science ®Google Scholar
• RabbaniAAlexanderGCOut-of-pocket and total costs of fixed-dose combination antihypertensives and their componentsAm J Hypertens200821550951318437141
   PubMed Web of Science ®Google Scholar
• SaitoIKobayashiMMatsushitaYMoriAKawasugiKSarutaTCost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation modelHypertens Res20083171373138318957808
   PubMed Web of Science ®Google Scholar
• TakaseBTakeishiYHiraiTComparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertensionCirc J200872576476918441457
   PubMed Web of Science ®Google Scholar
• NeutelJMComplementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertensionPostgrad Med20091212404819332961
   PubMed Web of Science ®Google Scholar